Loading organizations...
Key people at Elizabeth Glaser Pediatric AIDS Foundation.
Founded in 1988 by Elizabeth Glaser, Susan DeLaurentis, and Susan Zeegan, the Elizabeth Glaser Pediatric AIDS Foundation is a Washington, DC-based nonprofit organization dedicated to ending pediatric HIV globally. Under the leadership of President and CEO Charles Lyons, the entity funds vital medical research, global advocacy initiatives, and health system strengthening programs to prevent mother-to-child disease transmission. Operating primarily through charitable donations, research grants, and fundraising events, the foundation provides essential medical and technical expertise to various high-burden regions worldwide. Over its more than 30 years of continuous operation, the organization has driven major federal legislative efforts like the Ryan White Care Act and the Pediatric Research Equity Act. Furthermore, these supported initiatives have directly contributed to a remarkable 95 percent drop in childhood HIV infections within the United States and a 50 percent decline worldwide.
Key people at Elizabeth Glaser Pediatric AIDS Foundation.
The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) is a nonprofit organization dedicated to ending HIV/AIDS in children, youth, and families through research, advocacy, global programs, and strengthening health systems.[1][3][4] Founded in 1988, EGPAF focuses on preventing mother-to-child transmission (MTCT) of HIV, providing treatment services, and integrating HIV care with family planning and reproductive health, operating in 12 countries primarily in Africa.[2][4][5] Key achievements include reducing U.S. pediatric HIV infections by 95%, protecting 4.4 million children via PMTCT programs, and supporting over 15,000 HIV service sites worldwide, with MTCT preventable 93% of the time through proper treatment.[1]
EGPAF's work emphasizes comprehensive responses: research into pediatric treatments, advocacy for funding and policy, and on-the-ground capacity building for governments and communities in high-burden regions.[2][3] It has cut global pediatric HIV infections by 50% and served over 33 million pregnant women with lifesaving services.[1]
EGPAF traces its roots to 1981, when Elizabeth Glaser contracted HIV via a blood transfusion during her daughter Ariel's birth, unknowingly transmitting it to Ariel through breastfeeding and later to her son Jake during pregnancy.[1][3][4] In 1985, Ariel's unexplained illnesses revealed advanced pediatric AIDS, for which no treatments existed; she died in 1988 despite the Glaser family's fight for AZT access, approved only for adults.[4]
Refusing defeat, Elizabeth co-founded the Pediatric AIDS Foundation in 1988 with friends Susan DeLaurentis and Susie Zeegen to fund research, raise awareness, and develop pediatric HIV drugs and MTCT prevention.[1][4] Elizabeth's 1992 Democratic National Convention speech criticized federal underfunding, amplifying the cause; her 1991 autobiography *In the Absence of Angels* shared their story.[4] She passed in 1994, prompting the foundation's renaming in her honor.[4] Over 35+ years, EGPAF has evolved from U.S.-focused advocacy to global leadership in pediatric AIDS elimination.[1][2]
While not a tech company, EGPAF leverages health technology innovations like diagnostics, telemedicine, and data systems to scale HIV services in low-resource settings, riding trends in digital health for global public health equity.[2][9] Its timing aligns with post-2020 gains in MTCT prevention amid ongoing challenges—10,000 weekly adolescent infections—positioning it to influence Universal Health Coverage via integrated HIV-family planning in Africa.[1][5] Market forces like donor funding, PEPFAR support, and tech-enabled tracking favor expansion, as EGPAF strengthens local systems and advocates for neglected pediatric needs, shaping ecosystems for scalable, tech-supported interventions.[7]
EGPAF is sharpening its singular goal: ending pediatric HIV/AIDS by intensifying expertise across children's health spectra, targeting millions untreated amid adolescent vulnerabilities.[1] Trends like AI-driven diagnostics, mRNA vaccines, and integrated telehealth will accelerate MTCT elimination and treatment access. Its influence may evolve toward tech-health hybrids, partnering with innovators for real-time data and prevention tools, sustaining Elizabeth's legacy of breakthroughs through focus—ensuring no child bears HIV's devastation.[1][7]
